Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS von Schulze, Christopher J., Seamon, Kyle J., Zhao, Yulei, Yang, Yu C., Cregg, Jim, Kim, Dongsung, Tomlinson, Aidan, Choy, Tiffany J., Wang, Zhican, Sang, Ben, Pourfarjam, Yasin, Lucas, Jessica, Cuevas-Navarro, Antonio, Ayala-Santos, Carlos, Vides, Alberto, Li, Chuanchuan, Marquez, Abby, Zhong, Mengqi, Vemulapalli, Vidyasiri, Weller, Caroline, Gould, Andrea, Whalen, Daniel M., Salvador, Anthony, Milin, Anthony, Saldajeno-Concar, Mae, Dinglasan, Nuntana, Chen, Anqi, Evans, Jim, Knox, John E., Koltun, Elena S., Singh, Mallika, Nichols, Robert, Wildes, David, Gill, Adrian L., Smith, Jacqueline A. M., Lito, Piro

Volltext

Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy von Holderfield, Matthew, Lee, Bianca J., Jiang, Jingjing, Tomlinson, Aidan, Seamon, Kyle J., Mira, Alessia, Patrucco, Enrico, Goodhart, Grace, Dilly, Julien, Gindin, Yevgeniy, Dinglasan, Nuntana, Wang, Yingyun, Lai, Lick Pui, Cai, Shurui, Jiang, Lingyan, Nasholm, Nicole, Shifrin, Nataliya, Blaj, Cristina, Shah, Harshit, Evans, James W., Montazer, Nilufar, Lai, Oliver, Shi, Jade, Ahler, Ethan, Quintana, Elsa, Chang, Stephanie, Salvador, Anthony, Marquez, Abby, Cregg, Jim, Liu, Yang, Milin, Anthony, Chen, Anqi, Ziv, Tamar Bar, Parsons, Dylan, Knox, John E., Klomp, Jennifer E., Roth, Jennifer, Rees, Matthew, Ronan, Melissa, Cuevas-Navarro, Antonio, Hu, Feng, Lito, Piro, Santamaria, David, Aguirre, Andrew J., Waters, Andrew M., Der, Channing J., Ambrogio, Chiara, Wang, Zhengping, Gill, Adrian L., Koltun, Elena S., Smith, Jacqueline A. M., Wildes, David, Singh, Mallika

Volltext

Direct targeting of RAS in pancreatic ductal adenocarcinoma with RMC-6236, a first-in-class, RAS-selective, orally bioavailable, tri-complex RAS MULTI (ON) inhibitor von Gustafson, W. Clay, Wildes, David, Rice, Meghan A., Lee, Bianca J., Jiang, Jingjing, Wang, Zhengping, Chang, Stephanie, Flagella, Mike, Mu, Yunming, Dinglasan, Nuntana, Nasholm, Nicole, Evans, James W., Seamon, Kyle, Cregg, Jim, Bermingham, Alun, Freilich, Rebecca, Gill, Adrian L., Koltun, Elena, Smith, Jacqueline A, Singh, Mallika

Volltext

Abstract 1260: First-in-class, orally bioavailable KRASG12V(ON) tri-complex inhibitors, as single agents and in combinations, drive profound anti-tumor activity in preclinical mode... von Koltun, Elena, Cregg, Jim, Rice, Meghan A., Whalen, Dan M., Freilich, Rebecca, Jiang, Jingjing, Hansen, Richard, Bermingham, Alun, Knox, John E., Dinglasan, Jay, Seamon, Kyle, Blaj, Cristina, Chang, Stephanie S., Liu, Yang, Huang, Jun, Chou, Kang-Jye, McDowell, Laura, Lee, Bianca J., Wildes, David, Wang, Zhengping, Singh, Mallika, Gill, Adrian L., Smith, Jacqueline A.

Volltext

Abstract 1261: A next generation tri-complex KRASG12C(ON) inhibitor directly targets the active, GTP-bound state of mutant RAS and may overcome resistance to KRASG12C(OFF) inhibiti... von Nichols, Robert J., Cregg, Jim, Schulze, Christopher J., Wang, Zhican, Yang, Kevin, Jiang, Jingjing, Whalen, Daniel M., Hansen, Rich, Garrenton, Lindsay S., Bermingham, Alun, Knox, John E., Choy, Tiffany, Reyes, Denise, Rios, Mayra, Seamon, Kyle, Longhi, Michael, Chou, Kang-Jye, Li, Shaoling, Wildes, David P., Singh, Mallika, Koltun, Elena S., Gill, Adrian L., Smith, Jacqueline A. M.

Volltext

Abstract ND07: Discovery of RMC-6291, a tri-complex KRASG12C(ON) inhibitor von Cregg, Jim, Nichols, R J., Yang, Y C., Schulze, C J., Wang, Z, Dua, R, Jiang, J, Nasholm, N, Knox, J E., Seamon, K, Longhi, M, Tomlinson, A, Chou, K, Li, S, Wildes, D P., Singh, M, Koltun, E S., Gill, A L., Smith, J A.

Volltext

Abstract 3597: Direct targeting of KRASG12X mutant cancers with RMC-6236, a first-in-class, RAS-selective, orally bioavailable, tri-complex RASMULTI(ON) inhibitor von Koltun, Elena S., Rice, Meghan A., Gustafson, W. Clay, Wilds, David, Jiang, Jingjing, Lee, Bianca J., Wang, Zhengping, Chang, Stephanie, Flagella, Mike, Mu, Yunming, Dinglasan, Nuntana, Nasholm, Nicole, Evans, James W., Wang, Yingyun, Seamon, Kyle, Liu, Yang, Blaj, Cristina, Knox, John, Freilich, Rebecca, Quintana, Elsa, Cregg, Jim, Bermingham, Alun, Gill, Adrian L., Smith, Jacqueline Am, Singh, Mallika

Volltext

Abstract 3598: A first-in-class tri-complex KRASG13C(ON) inhibitor validates therapeutic targeting of KRASG13Cand drives tumor regressions in preclinical models von Schulze, Christopher J., Cregg, Jim, Seamon, Kyle J., Yang, Yu Chi, Wang, Zhican, Garrenton, Lindsay S., Bermingham, Alun, Knox, John E., Tomlinson, Aidan, Chou, Kang-Jye, Li, Shaoling, Wildes, David P., Singh, Mallika, Koltun, Elena S., Gill, Adrian L., Nichols, Robert J., Smith, Jacqueline A.

Volltext

Abstract 3595: RMC-6291, a next-generation tri-complex KRASG12C(ON) inhibitor, outperforms KRASG12C(OFF) inhibitors in preclinical models of KRASG12C cancers von Nichols, Robert J., Yang, Y.C., Cregg, Jim, Schulze, Chris J., Wang, Zhican, Dua, Richa, Jiang, Jingjing, Garrenton, Lindsay S., Nasholm, Nicole, Bermingham, Alun, Knox, John E., Seamon, Kyle, Longhi, Michael, Chou, Kang-Jye, Li, Shaoling, Wildes, David P., Singh, Mallika, Koltun, Elena S., Gill, Adrian L., Smith, Jacqueline A.M.

Volltext

Mutations in the FAD-binding fold of alcohol oxidase from Hansenula polymorpha von Hoop, Meltsje de, Asgeirsdottir, Sigridur, Blaauw, Mieke, Veenhuis, Marten, Cregg, Jim, Gleeson, Martin, AB, Geert

Volltext